摘要
目的全面评价固定剂量复合剂卫非特／卫非宁的抗结核疗效、患者合作情况和在我国应用的前景。方法将３０８例初治菌阳肺结核患者，以２∶１随机对照法分为治疗组（２ＲＩＦＡＴＥＲ／４ＲＩＦＩＮＡＨ，２２７例）和对照组（２ＨＲＺ／４ＨＲ，８１例）进行短程化疗。结果治疗组和对照组２个月痰菌阴转率分别达９１．２％和８６．４％；满疗程痰菌阴转率各为９８．７％和９７．５％；胸部Ｘ线明显改善，治疗组和对照组病灶吸收分别占９５．２％和９３．８％，两组分别有６８．６％和６７．９％空洞闭合；两组药物不良反应发生率均为８．９％；治疗组和对照组自动停药率分别为４．２％和７．８％。结论固定复合剂卫非特／卫非宁是一种安全、高效、易被患者接受、在中国结核病短化中有推广应用前景的抗结核药物。
Objective To assess antituberculous efficacy, patients′ compliance and application perspective of fixed dose compounds rifater/rifinah in China. Method Three hundred eight new smear positive pulmonary tuberculosis patients were randomly allocated with a ratio of 2 to 1 into treatment group (227 cases, receiving 2RIFATER/4RIFINAH regimen) and controls (81 cases, 2HRZ/4HR) for observation. Result The sputum negative conversion rates at the 2nd month in the treatment group and the controls were 91.2% and 86.4% respectively, and at the end of the chemotherapy 98.7% and 97.5%. Chest radiography showed remarkable improvement. The resolution of pulmonary lesions in the treatment group and the controls accounted for 95.2% and 93.8% respectively, with cavity closure rates of 68.6% in the treatment group and 67.9% in the controls. The drug adverse reaction rates were 8.9% in both groups, and the default rates were 4.3% and 7.8% respectively. Conclusion Fixed dose compounds rifater/rifinah show excellent therapeutic efficacy, safety and compliance in antituberculous chemotherapy, which could be recommended for wider use in tuberculosis control in China.
出处
《中华结核和呼吸杂志》
CAS
CSCD
北大核心
1998年第11期645-647,共3页
Chinese Journal of Tuberculosis and Respiratory Diseases
关键词
肺结核
药物疗法
卫非特
卫非宁
Tuberculosis, pulmonary Drug therapy, combination Rifater Rifinah
